慢性阻塞性肺疾病治疗药物研究进展

罗志成; 吴国振; 袁星

doi:10.3969/j.issn.1006-0111.2017.03.003

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

1.
江西中医药大学药学院, 江西南昌 330004
2.
第二军医大学药学院, 上海 200433

Research progress in drugs for chronic obstructive pulmonary disease therapy

1.
School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China
2.
School of Pharmacy, Second Military Medical University, Shanghai 200433, China

摘要: 慢性阻塞性肺疾病（COPD）是一种气流受限且不完全可逆，同时病情进行性加重的慢性呼吸系统疾病。COPD病理机制复杂，病症主要包括肺功能降低、气道及肺组织慢性炎症、咳嗽、消瘦、活动量减少等。以往临床上一般采用支气管扩张剂和抗炎药物对COPD进行治疗，随着对该疾病病理机制的深入研究，抗氧化治疗也已逐渐应用于临床。笔者现对包括支气管扩张剂、抗炎药物及抗氧化治疗药物在内的COPD治疗药物的研究进展进行综述。
- 慢性阻塞性肺疾病 /
- 治疗药物 /
- 支气管扩张 /
- 抗炎 /
- 抗氧化
Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and progressive course. The pathogenesis of COPD is complicated. Clinical symptoms include declining pulmonary function, airway and lung inflammation, cough, emaciation, low activity and so on. In the past, the medications for COPD treatment were mainly bronchodilators and anti-inflammatory drugs.With the better understanding of its pathogenesis, anti-oxidative drugs have also been used in the clinical treatment of COPD recently. This article reviews the development of drugs which include bronchodilators, anti-inflammatory drugs and anti-oxidative drugs for the therapy of COPD.
- COPD /
- drugs for therapy /
- bronchiectasis /
- anti-inflammatory /
- anti-oxidant

[1]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)(二)[J]. 全科医学临床与教育, 2013, 36(6): 484-491.
[2]	Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
[3]	丁宁, 王胜. 慢性阻塞性肺疾病发病机制最新研究进展[J]. 临床肺科杂志, 2016, 21(1): 133-136.
[4]	徐庆庆, 李向阳. 抗胆碱能药物在慢性阻塞性肺疾病中的临床应用[J]. 中国医药指南, 2015, 13(29): 37-39.
[5]	任艳平, 石蕊, 张睿,等. 噻托溴铵治疗慢性阻塞性肺疾病有效性和安全性的Meta分析[J]. 中国药房, 2015, 26(21): 2947-2949.
[6]	夏玲红, 孙黎, 金冠钦,等. 治疗慢性阻塞性肺病新药阿地溴铵[J]. 中国新药杂志, 2013, 22(5): 499-501.
[7]	Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the anttainstudy[J]. Eur Respir J, 2012, 40(4): 830-836.
[8]	Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the glow2 study[J]. Eur Respir J, 2012, 40(5): 1106-1114.
[9]	Kew K. Long-acting beta2-agonists for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2006, 3(3): 117-118.
[10]	Kornmann O, Dahl R, Centanni S, et al. Once daily indacaterol versus twice daily salmeterol for COPD: a placebo controlled comparison[J]. Euro Respir J, 2011, 37(2): 273-279.
[11]	李媛, 林青. 茶碱类药物的研究进展及应用[J]. 中国医药指南, 2013, 11(4): 421-422.
[12]	Iiboshi H, Ashitani J, Katoh S. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-α in the sputum of patients with chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2007, 20(1): 46-51.
[13]	Barnes PJ. Theophylline: new perspectives for an old drug[J]. Am J Respir Crit Care Med, 2003, 167(6): 813-818.
[14]	赵新云, 孔辉, 解卫平. 炎症反应与慢性阻塞性肺疾病肺功能分级[J]. 国际呼吸杂志, 2013, 33(17): 1343-1346.
[15]	钟佰强, 钱丽芬, 黄宝贤,等. 不同剂量糖皮质激素对慢性阻塞性肺疾病患者急性加重期炎性介质的影响及临床意义[J]. 中华老年医学杂志, 2014, 33(4): 376-379.
[16]	Battaglia S, Cardillo I, Lavorini F, et al. Safety considerations of inhaled corticosteroids in the elderly[J]. Drugs Aging, 2014, 31(11): 787-796.
[17]	赵焕, 石寒冰, 毕红霞. 布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病的临床疗效观察[J]. 中国全科医学, 2013, 15(35): 4219-4221.
[18]	Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis[J].Pulm Pharmacol Ther, 2014, 27(1): 83-89.
[19]	宋毅, 徐莉琼, 李婵,等. 孟鲁司特治疗慢性阻塞性肺病65例疗效观察[J]. 四川医学, 2012, 33(3): 436-438.
[20]	李强, 邹小新, 饶常红. 孟鲁司特联合噻托溴铵治疗慢性阻塞性肺疾病疗效的研究[J]. 重庆医学, 2013, 42(19): 2278-2280.
[21]	Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD[J]. N Engl J Med, 2011, 365(8): 689-698.
[22]	Neukamm A, HΦiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial[J].J Intern Med, 2014, 278(1): 59-67.
[23]	王翠茹, 李玲, 韩云霞,等. 慢性阻塞性肺疾病发病机制的研究进展[J]. 当代医学, 2011, 17(32): 19-20.
[24]	Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine[J]. COPD, 2014, 11(6): 705-717.
[25]	Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1 year, double-blind, randomized, placebo-controlled HIACE study[J]. Chest, 2013, 144(1): 106-118.
[26]	张瑞. 盐酸氨溴索雾化对COPD患者氧化应激的影响[J]. 临床肺科杂志, 2013, 18(5): 894-895.
[27]	Esposito A, Valentino MR, Bruzzese D, et al. Effect of carbocisteine in prevention of exacerbation of chronic obstructive pulmonary disease (CAPRI study): an observational study[J].Pulm Pharmacol Ther, 2016, 37(1): 85-88.
[28]	Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice[J].Proc Natl Acad Sci USA, 2009, 106(1): 250-255.
[29]	Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease[J].J Cell Biochem, 2012, 113(3): 752-759.
[30]	He X, Wang L, Szklarz G, et al. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway[J].J Pharmacol Exp Ther, 2012, 342(1): 81-90.
[31]	Youn GS, Kwon DJ, Ju SM, et al. Curcumin ameliorates TNF-α-induced ICAM-1 expression and subsequent THP-1 adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells[J].BMB Rep, 2013, 46(8): 410-415.

[1]	段禹, 刘爱军. 活血化瘀法治疗血管性痴呆的研究进展 . 药学实践与服务, 2025, 43(4): 151-155, 173. doi: 10.12206/j.issn.2097-2024.202408045
[2]	葛鹏程, 苏日古嘎, 任天舒, 党大胜. 硫酸黏菌素联合头孢哌酮舒巴坦治疗泛耐药鲍曼不动杆菌肺内感染的疗效分析 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202404093
[3]	王文涛, 高兴, 赵凤平, 郑灿辉, 陈新. 异硒唑酮类化合物在疾病治疗中的作用和化学合成方法 . 药学实践与服务, 2025, 43(8): 367-372. doi: 10.12206/j.issn.2097-2024.202308064
[4]	卢熠菲, 宋佳, 沈红霞, 赵庆杰. 新型苦参碱衍生物的设计合成与体外抗炎活性研究 . 药学实践与服务, 2025, 43(): 1-8. doi: 10.12206/j.issn.2097-2024.202503005
[5]	关梦瑶, 夏天爽, 何旭辉, 史策, 蒋益萍, 辛海量. 黑蒜多糖抗便秘作用研究 . 药学实践与服务, 2025, 43(4): 190-194. doi: 10.12206/j.issn.2097-2024.202403059
[6]	李锐, 张倩倩, 王瑞冬, 高小峰. 国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(1): 41-46. doi: 10.12206/j.issn.2097-2024.202408031
[7]	闻韬, 焦广洋, 赵梦沛, 岳小强, 张凤, 陈万生. 基于UHPLC-Q-TOF/MS结合网络药理学研究柴胡桂枝干姜汤治疗慢性非萎缩性胃炎的物质基础及疗效机制 . 药学实践与服务, 2025, 43(9): 455-462. doi: 10.12206/j.issn.2097-2024.202312061
[8]	高洁, 林心兰, 王兆骞, 张青亭, 李静静, 张凤. 生物制剂治疗强直性脊柱炎的研究进展 . 药学实践与服务, 2025, 43(7): 320-324. doi: 10.12206/j.issn.2097-2024.202502005
[9]	吴若南, 叶爽, 李墨晨轩, 缪震元, 罗川. 冬凌草甲素磺酰脲衍生物的设计与抗炎活性研究 . 药学实践与服务, 2025, 43(7): 335-338, 352. doi: 10.12206/j.issn.2097-2024.202401048
[10]	陶宫佳, 陈林林, 宋泽成, 刘梦肖, 王彦. 苦参碱及衍生物的抗炎作用及其机制研究进展 . 药学实践与服务, 2025, 43(4): 163-168, 194. doi: 10.12206/j.issn.2097-2024.202406035
[11]	段虎, 周艳卿, 钱瑜琳, 赵亮. 某二级医院稳定期慢性阻塞性肺疾病患者吸入治疗依从性及其影响因素 . 药学实践与服务, 2025, 43(7): 362-366. doi: 10.12206/j.issn.2097-2024.202204094
[12]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[13]	修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星. 全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
[14]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[15]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[16]	何亚伦, 祁智, 常杰. 消胀通便膏在晚期肝癌患者阿片类药物相关性便秘中的应用研究 . 药学实践与服务, 2024, 42(12): 520-523. doi: 10.12206/j.issn.2097-2024.202309009
[17]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[18]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[19]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察 . 药学实践与服务, 2024, 42(12): 524-527, 532. doi: 10.12206/j.issn.2097-2024.202405035
[20]	赖立勇, 夏天爽, 徐圣焱, 蒋益萍, 岳小强, 辛海量. 中药青蒿抗氧化活性的谱效关系研究 . 药学实践与服务, 2024, 42(5): 203-210, 216. doi: 10.12206/j.issn.2097-2024.202211012

点击查看大图

计量

文章访问数: 4560
HTML全文浏览量: 542
PDF下载量: 1220
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

Research progress in drugs for chronic obstructive pulmonary disease therapy

计量

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

1. 江西中医药大学药学院, 江西南昌 330004

2. 第二军医大学药学院, 上海 200433

English Abstract

Research progress in drugs for chronic obstructive pulmonary disease therapy

1. School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

2. School of Pharmacy, Second Military Medical University, Shanghai 200433, China

全文HTML

目录

留言板

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

Research progress in drugs for chronic obstructive pulmonary disease therapy

计量

出版历程

慢性阻塞性肺疾病治疗药物研究进展

doi: 10.3969/j.issn.1006-0111.2017.03.003

1. 江西中医药大学药学院, 江西 南昌 330004 2. 第二军医大学药学院, 上海 200433

English Abstract

Research progress in drugs for chronic obstructive pulmonary disease therapy

1. School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China 2. School of Pharmacy, Second Military Medical University, Shanghai 200433, China

全文HTML

目录

1. 江西中医药大学药学院, 江西南昌 330004

2. 第二军医大学药学院, 上海 200433

1. School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

2. School of Pharmacy, Second Military Medical University, Shanghai 200433, China